Plasma authorization forces rethink of COVID-19 antibody trials

Individuals who have received or plan to receive convalescent plasma are excluded from ongoing clinical trials of two COVID-19 antiviral mAb therapies — REGn-COV2 from Regeneron and LY-CoV555 from Lilly and AbCellera — that may soon need to change.

The trials were designed before emergency use authorization (EUA) made convalescent plasma therapy a contender for standard of care for COVID-19. ...